Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Syrosingopine has selective depleting effect on brain amines is potentiated by combined treatment with disulfiram or fusaric acid, a dopamine beta-hydroxylase inhibitor.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 14,000 | |||
5 mg | 在庫あり | ¥ 33,500 | |||
10 mg | 在庫あり | ¥ 51,500 | |||
25 mg | 在庫あり | ¥ 87,500 | |||
50 mg | 在庫あり | ¥ 131,500 | |||
100 mg | 在庫あり | ¥ 181,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 49,000 |
説明 | Syrosingopine has selective depleting effect on brain amines is potentiated by combined treatment with disulfiram or fusaric acid, a dopamine beta-hydroxylase inhibitor. |
In vitro | The anticancer activity of the widely used diabetic drug metformin is strongly potentiated by Syrosingopine. Synthetic lethality elicited by combining the two drugs is synergistic and specific to transformed cells. This effect is unrelated to Syrosingopine??s known role as an inhibitor of the vesicular monoamine transporters. Syrosingopine binds to the glycolytic enzyme α±-enolase in vitro, and the expression of the γ-enolase isoform correlates with nonresponsiveness to the drug combination. Syrosingopine sensitized cancer cells to metformin and its more potent derivative phenformin far below the individual toxic threshold of each compound[1] |
植物由来 |
分子量 | 666.71 |
分子式 | C35H42N2O11 |
CAS No. | 84-36-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 62.5 mg/mL (93.74 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Syrosingopine 84-36-6 GPCR/G Protein Neuroscience Dopamine Receptor cancer NAD+ Su-3118 MCTs Su 3118 synthetic lethality inhibit metformin lactate glycolysis Su3118 Monocarboxylate Transporter Inhibitor inhibitor